JP2019505554A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505554A5
JP2019505554A5 JP2018543637A JP2018543637A JP2019505554A5 JP 2019505554 A5 JP2019505554 A5 JP 2019505554A5 JP 2018543637 A JP2018543637 A JP 2018543637A JP 2018543637 A JP2018543637 A JP 2018543637A JP 2019505554 A5 JP2019505554 A5 JP 2019505554A5
Authority
JP
Japan
Prior art keywords
vaccine
antagonist
infection
dose
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543637A
Other languages
English (en)
Japanese (ja)
Other versions
JP7597500B2 (ja
JP2019505554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/018487 external-priority patent/WO2017143270A1/en
Publication of JP2019505554A publication Critical patent/JP2019505554A/ja
Publication of JP2019505554A5 publication Critical patent/JP2019505554A5/ja
Priority to JP2022152120A priority Critical patent/JP7813209B2/ja
Priority to JP2024087570A priority patent/JP2024112987A/ja
Application granted granted Critical
Publication of JP7597500B2 publication Critical patent/JP7597500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543637A 2016-02-19 2017-02-17 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法 Active JP7597500B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022152120A JP7813209B2 (ja) 2016-02-19 2022-09-26 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2024087570A JP2024112987A (ja) 2016-02-19 2024-05-30 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662297257P 2016-02-19 2016-02-19
US62/297,257 2016-02-19
US201662409936P 2016-10-19 2016-10-19
US62/409,936 2016-10-19
PCT/US2017/018487 WO2017143270A1 (en) 2016-02-19 2017-02-17 Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022152120A Division JP7813209B2 (ja) 2016-02-19 2022-09-26 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法

Publications (3)

Publication Number Publication Date
JP2019505554A JP2019505554A (ja) 2019-02-28
JP2019505554A5 true JP2019505554A5 (enExample) 2020-03-26
JP7597500B2 JP7597500B2 (ja) 2024-12-10

Family

ID=58192407

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543637A Active JP7597500B2 (ja) 2016-02-19 2017-02-17 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2022152120A Active JP7813209B2 (ja) 2016-02-19 2022-09-26 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2024087570A Abandoned JP2024112987A (ja) 2016-02-19 2024-05-30 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022152120A Active JP7813209B2 (ja) 2016-02-19 2022-09-26 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2024087570A Abandoned JP2024112987A (ja) 2016-02-19 2024-05-30 Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法

Country Status (17)

Country Link
US (3) US10314904B2 (enExample)
EP (2) EP3416685B1 (enExample)
JP (3) JP7597500B2 (enExample)
KR (1) KR102868264B1 (enExample)
CN (1) CN109069625A (enExample)
AU (2) AU2017220184B2 (enExample)
CA (1) CA3014202A1 (enExample)
ES (1) ES2983475T3 (enExample)
HU (1) HUE067673T2 (enExample)
IL (1) IL261025A (enExample)
MA (1) MA44238B1 (enExample)
MX (2) MX2018009990A (enExample)
PL (1) PL3416685T3 (enExample)
PT (1) PT3416685T (enExample)
RU (1) RU2753869C2 (enExample)
WO (1) WO2017143270A1 (enExample)
ZA (1) ZA201805295B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
WO2017196943A1 (en) * 2016-05-10 2017-11-16 Minneapolis Medical Research Foundation Cytokine signaling immunomodulators and methods
HUE067888T2 (hu) * 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
MX2021010560A (es) * 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
MX2022011730A (es) * 2020-03-27 2022-10-13 Regeneron Pharma Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
US20240336688A1 (en) * 2021-07-22 2024-10-10 Icahn School Of Medicine At Mount Sinai Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
IL310962A (en) * 2021-08-23 2024-04-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an IL-4R antagonist
CN118717989A (zh) * 2024-05-27 2024-10-01 中国人民解放军军事科学院军事医学研究院 Il-4r拮抗剂在制备预防和/或治疗流感病毒感染的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20120088814A1 (en) * 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
EP3530283A1 (en) * 2012-06-05 2019-08-28 The Australian National University Vaccination with interleukin-4 antagonists
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
KR20190062142A (ko) * 2017-11-28 2019-06-05 (주)비티엔 면역 증강 활성을 가지는 아미노산 미네랄 복합체 및 이를 포함하는 식품, 약학 또는 사료용 조성물
US20210361700A1 (en) * 2020-05-22 2021-11-25 Trustees Of Tufts College Nutritional supplement to combat covid-19 and aid vaccination

Similar Documents

Publication Publication Date Title
JP2019505554A5 (enExample)
JP7813209B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
Wagner et al. Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives
US10406220B2 (en) Pneumococcal dosing regimen
Plotkin et al. The development of vaccines: how the past led to the future
Locht Live pertussis vaccines: will they protect against carriage and spread of pertussis?
Li et al. Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications
Moylett et al. 29. Immunization
Moore Developing vaccines to combat human diseases: a history
Ottolini Current and future use of vaccines for viral and bacterial respiratory tract infections
Hay What you need to know
AbdelAllah et al. A combined inactivated cholera and hepatitis A vaccine-induced potent protective immunity in a mouse model
HK40117172A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
Mishra 43 Recent Advances for Immunotherapies Against Infectious Disease
Božić et al. An overview of current vacccines for the prophylaxis of bacterical infections Pres
Backx et al. Immunization
CN117562989A (zh) 用疫苗控制感染性疾病的方法
Raya et al. 153. The Effect of Timing of Tetanus–Diphtheria and Pertussis Vaccine Administration in Pregnancy on The Avidity of Pertussis Antibodies
Miranda Early Childhood Vaccination Schedules in European Union Countries: A Review
MOON Pertussis Booster Protects Teens Beyond 5 Years
HK40001760B (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
HK40001760A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
Bhat et al. Adolescent Vaccines